4.7 Article

Trial design on prophylaxis and treatment of brain metastases: Lessons learned from the EORTC Brain Metastases Strategic Meeting 2012

Journal

EUROPEAN JOURNAL OF CANCER
Volume 48, Issue 18, Pages 3439-3447

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2012.07.002

Keywords

Brain metastases; Clinical trail; Prophylaxis; EORTC

Categories

Funding

  1. Roche
  2. Novocure
  3. Merck Serono
  4. Comprehensive Cancer Center Vienna
  5. Genentech
  6. EU
  7. Dutch Epilepsy Foundation (NEF)
  8. Dutch Cancer Society (KWF Kankerbestrijding)
  9. Foundation NutsOhra
  10. Foundation STOPhersentumoren. nl
  11. National Brain Tumor Foundation/Tug McGraw Foundation
  12. UCB
  13. Sanofi-Aventis
  14. GSK

Ask authors/readers for more resources

Brain metastases (BM) occur in a significant proportion of cancer patients and are associated with considerable morbidity and poor prognosis. The trial design in BM patients is particularly challenging, as many disease and patient variables, statistical issues, and the selection of appropriate end-points have to be taken into account. During a meeting organised on behalf of the European Organisation for Research and Treatment of Cancer (EORTC), methodological aspects of trial design in BM were discussed. This paper summarises the issues and potential trial strategies discussed during this meeting and may provide some guidance for the design of trials in BM patients. (C) 2012 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available